首页期刊介绍编委会投稿指南期刊订阅广告合作留言板联系我们English
吕建敏,龚金炎,刘士旺.秀珍菇粉对 H22 荷瘤小鼠体内抗肿瘤作用研究[J].中国实验动物学报,2020,28(2):0.
秀珍菇粉对 H22 荷瘤小鼠体内抗肿瘤作用研究
Anti-tumor activities of Pleurotus geesteranus fruit body powder on H22 tumor-bearing mice
投稿时间:2019-08-30  
DOI:10. 3969 / j.issn.1005-4847. 2020. 02. 010
中文关键词:  秀珍菇  抗肿瘤  H22 荷瘤小鼠  免疫功能  抗氧化能力
英文关键词:Pleurotus geesteranus  anti-tumor  H22 tumor-bearing mice  immune function  antioxidant function
基金项目:
作者单位E-mail
吕建敏 浙江中医药大学动物实验研究中心/ 比较医学研究所,杭州 310053 ljm6666@ 163.com 
龚金炎 浙江科技学院生物与化学工程学院/ 轻工学院,杭州 310023  
刘士旺 浙江科技学院生物与化学工程学院/ 轻工学院,杭州 310023  
摘要点击次数: 212
全文下载次数: 25
中文摘要:
      目的 本试验旨在研究秀珍菇抗肿瘤作用及其抑瘤机制。 方法 选用 ICR 雄性小鼠 60 只,取 10 只作为空白组,剩余 50 只小鼠通过腋部皮下接种 H22 小鼠腹水构建荷瘤小鼠模型,造模后随机分为模型组、阳性 药(CTX)组、秀珍菇低、中、高剂量组,每组 10 只。 模型组小鼠灌服生理盐水,阳性药组小鼠按 20 mg / kg 体重隔天腹腔注射注射环磷酰胺(CTX)生理盐水溶液,秀珍菇低、中、高剂量组小鼠分别按 750、1500、3000 mg / kg 体重每天 剂量灌服秀珍菇生理盐水混悬液。 给药 10 d 后,测定各组小鼠平均瘤重,肿瘤抑制率;测定免疫器官脏器指数、血清免疫球蛋白和细胞因子含量;测定肝、肾抗氧化指标;观察肿瘤和脾组织 HE 染色病理切片。 结果 (1)CTX 及 秀珍菇低、中、高剂量组小鼠的平均瘤重均极显著低于模型组(P< 0. 01),四组小鼠肿瘤抑制率分别为 55. 18%, 29. 06%、47. 47%和 48. 80%。 (2)与空白组比较,模型组小鼠脾指数、血清 IgA 和 TNF-α 含量及肝 MDA 含量显著升高(P< 0. 05,P< 0. 01),血清 IL-6 含量有上升趋势(P0. 05),而血清 IL-2 含量、肝 CAT 和 GSH-Px 活性及肾 SOD、 GSH-Px 和 CAT 活性显著降低(P< 0. 05,P< 0. 01);同时,CTX 组小鼠胸腺指数显著低于空白组(P< 0. 05)。 (3)秀珍菇对荷瘤小鼠免疫和抗氧化功能异常改变具有逆转作用:与模型组比较,秀珍菇各剂量组小鼠血清 IgA 和 TNF-α 含量及高剂量组小鼠 IL-6 水平显著降低(P < 0. 05,P < 0. 01),低剂量组小鼠血清 IL-2 水平显著升高(P < 0. 01); 秀珍菇处理还显著提高了各剂量组荷瘤小鼠肝 CAT 活性及肾 SOD 和 CAT 活性(P < 0. 05,P < 0. 01),显著升高 中、高剂量组肝 GSH-Px 活性和低、中剂量组肾 GSH-Px 活性(P < 0. 05,P < 0. 01),并显著降低中剂量组的肝 MDA 含量(P < 0. 05)。 (4)与 CTX 组比较,秀珍菇高剂量组小鼠脾指数显著提高(P < 0. 05),而血清 IL-6 水平显著降 低(P < 0. 05)。 (5)肿瘤组织病理切片显示 CTX 组和秀珍菇各剂量组的肿瘤坏死面积明显增加。 结论 秀珍菇可抑制 H22 实体移植瘤生长,其机制与其具有较强的免疫调节和抗氧化作用有关。
英文摘要:
      Objective To investigate the anti-tumor effects and mechanism of Pleurotus geesteranus powder (PGP) on H22 tumor-bearing mice. Methods The mouse tumor-bearing model was established by subcutaneous injection of ascites of H22 hepatocellular carcinoma into mice via the axilla. Sixty male ICR mice were randomly divided into one blank control (C) and five H22 tumor-bearing groups including tumor model control, positive control (cyclophosphamide, CTX) and three PGP groups. The mice in the model control group received 0. 9% saline solution by oral gavage, the mice in the positive control group were intra-abdominally injected with CTX saline solution (20 mg / kg body weight every other day), and mice in the PGP-treated groups were administered PGP (dispersed in 0. 9% saline solution) at low (750 mg / kg body weight, PGP-L), mid (1500 mg / kg body weight, PGP-M) and high (3000 mg / kg body weight, PGP-H) doses per day. The administration cycle was 10 d. When the trial was finished, the mean tumor weight, tumor inhibition rate and immune organ index were calculated, and the levels of serum immunoglobulins and cytokines, and antioxidant parameters in the liver and kidney were determined. Microscopic morphology of tumor and spleen tissues were observed by hematoxylin and eosin ( HE) staining. Results ( 1) The mean tumor weight in the CTX and three PGP groups was significantly decreased compared with the model control (P< 0. 01). The tumor inhibition rate in the CTX and three PGP groups (low, mid, high) were 55. 18%, 29. 06%, 47. 47%, and 48. 80%, respectively. ( 2) Compared with the blank control, the spleen index (P < 0. 01), levels of serum immunoglobulin A (IgA, P< 0. 01) and tumor necrosis factor α (TNF-α, P< 0. 05), and liver malondialdehyde (MDA, P< 0. 05) were increased in the model group, whereas serum interleukiN-2 (IL-2) content (P< 0. 01), activities of liver catalase (CAT, P< 0. 01), glutathione peroxidase (GSH-Px, P< 0. 01), kidney superoxide dismutase (SOD, P< 0. 01), GSH-Px (P< 0. 05), and CAT (P< 0. 01) in the model group were significantly decreased. Furthermore, the serum IL-6 content in the model group tended to be increased (P > 0. 05). The thymus index in the CTX group was significantly higher than in the blank control (P< 0. 05). (3) Treatment with PGP reversed the above abnormal performance in the model control. Levels of IgA and TNF-α in the three PGP treated ( low, mid, high) groups (IgA: P < 0. 01, P < 0. 01, P < 0. 01; TNFα: P < 0. 05, P < 0. 01, P < 0. 05), IL-6 levels in the PGP-H group (P< 0. 05), and liver MDA content in the PGP-M group (P<0. 05) were lower than in the model control group. IL-2 levels in the PGP-L group (P<0. 05), activities of liver CAT (P< 0. 05, P< 0. 05, P< 0. 01), kidney CAT (P< 0. 01, P< 0. 01, P< 0. 01) and kidney SOD (P< 0. 01, P< 0. 01, P< 0. 01) in three PGP-treated ( low, mid, high) groups, liver GSH-Px in the PGP-M and PGP-H groups (P< 0. 05), and kidney GSH-Px in the PGP-L and PGP-M groups (P< 0. 01) were significantly higher than in the model control group. ( 4) Compared with the CTX group, the spleen index in the PGP-H group was increased, and IL-6 levels were decreased significantly ( P < 0. 05 ). ( 5 ) Furthermore, compared with the model control group, increased necrotic areas of tumors in the CTX group and all PGP groups were observed by HE staining. Conclusions PGP might have anti-tumor effects related to its immunoregulatory and antioxidant functions.
查看全文  查看/发表评论  下载PDF阅读器
关闭
您是第 1575157 位访问者
版权所有:中国实验动物学会 主管单位:中国科学技术协会 主办单位:中国实验动物学会    中国医学科学院医学实验动物研究所
地  址: 北京市朝阳区潘家园南里5号 邮编:100021 电话:010-67779337 E-mail:bjb2@cnilas.org
本系统由北京勤云科技发展有限公司设计
微信关注二维码